Clinical trials: ADPKD
Autosomal Dominant Polycystic Kidney Disease
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
The purpose of this study is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of…
- Trial name
- HCY (NCT05193981)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
ADPKD
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The proposed research will determine the effectiveness of blocking aldosterone for improving the health and function of arteries in patients with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT01853553
- Testing
- Spironolactone, Sugar pill
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Colorado, Denver
Liver Cyst, Polycystic Liver Disease
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
Patients with large hepatic cysts (> 5cm) may develop symptoms. These can be captured with the polycystic liver disease questionnaire (PLD-Q).
- Conditions
- Liver Cyst, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney, Autosomal Dominant Polycystic Liver Disease
- Trial name
- ATLAS (NCT05500157)
- Testing
- aspiration sclerotherapy versus laparoscopic fenestration
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
ADPKD
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
The objective of this study is to measure the influence of both short term water restriction and high water intake on total kidney volume, measured by Magnetic Resonance Imaging (MRI) scan in Autosomal Dominant Polycystic Kidney…
- Trial name
- NCT02776241
- Testing
- water
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Polycystic Kidney, Autosomal Dominant
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02494141
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Polycystic Kidney Disease
Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
We aimed to evaluate the hypothalamus-pituitary-adrenal axis in autosomal dominant polycystic kidney disease (ADPKD) patients. Twenty two ADPKD patients and 27 healthy subjects were enrolled.
- Trial name
- NCT00598377
- Testing
- Tetracosactin
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Lanreotide In Polycystic Kidney Disease Study
LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular…
- Trial name
- LIPS (NCT02127437)
- Testing
- Lanreotide, saline
- Where
- France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ADPKD
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A mild reduction in food intake significantly inhibits renal cyst growth in mouse models of ADPKD. The underlying mechanism was unknown at the time.
- Trial name
- Keto-ADPKD (NCT04680780)
- Testing
- Ketogenic diet, 3-days water-fasting, Control
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- University of Cologne
Autosomal Dominant Polycystic Kidney Disease
Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD
The purpose of this study is to determine whether patients with autosomal dominant polycystic kidney disease (ADPKD) present with abnormal endothelial function, increased levels of NOX4 activity and mitochondrial abnormalities…
- Trial name
- NCT03493802
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Chronic Kidney Disease (Stages 4 and 5)
Thyroid Hormones in CKD
This is a retrospective, observational, study evaluating circulating thyroid hormone profiles in patients with severe chronic kidney disease (CKD stages G4-G5, non-dialysis).
- Trial name
- THYROID-CKD (NCT07663773)
- Testing
- Laboratory measurements
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
This is a Phase 1, First-in-Human study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of PYC-003 in healthy adult participants and adult participants with confirmed PKD1…
- Trial name
- NCT06714006
- Testing
- PYC-003
- Where
- 12 sites in Australia, Hong Kong and 1 more
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- PYC Therapeutics
Polycystic Kidney Diseases
Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related complications are common…
- Trial name
- COMPLIK (NCT06036992)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Brest
Healthy Volunteers
A Study of RGLS8429 in Healthy Volunteers
Primary Objective To assess the safety and tolerability of single ascending doses of RGLS8429 Secondary Objectives To identify dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of a single SC dose of…
- Trial name
- NCT05429073
- Testing
- RGLS8429
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Regulus Therapeutics Inc.
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug-drug interaction (DDI) potential of GV-100 following oral administration in healthy…
- Trial name
- NCT07788014
- Testing
- GV-100
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gilva Therapeutics Inc.
Autosomal Dominant Polycystic Kidney Disease
The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe
EuroCYST initiative aims to build a large, well-characterized cohort of Autosomal Dominant polyCYSTic Kidney Disease (ADPKD) subjects who are followed in a longitudinal observational cohort study has the potential to identify…
- Trial name
- NCT02187432
- Where
- 14 sites in Belgium, Czechia and 8 more
- Volunteers
- 1,100 people
- Sponsor
- Andreas L. Serra
Kidney Transplant; Complications, Aneurysm, Brain
Evaluation of Nephrectomy Specimen for Intracranial Aneurysm Development in ADPKD
ADPKD is the most common form of hereditary kidney disease and is known to occur in 1 of 400 to 1000 population in the U.S. ADPKD consists of 2.8% of patients receiving kidney transplantation in the investigator's center.
- Conditions
- Kidney Transplant; Complications, Aneurysm, Brain, Polycystic Kidney Diseases
- Trial name
- NCT03889392
- Testing
- Kidney transplantation and nephrectomy
- Volunteers
- 154 people
- Sponsor
- Asan Medical Center
Polycystic Kidney, Type 1 Autosomal Dominant Disease
Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic hereditary kidney disease in humans. ADPKD may affect all the generations of the ADPKD family and the probability of ADPKD is 50% in the second…
- Trial name
- ESPERANCE (NCT02948179)
- Testing
- Preimplantation Genetic Diagnosis
- Where
- 31 sites in China
- Volunteers
- 459 people
- Sponsor
- Changlin Mei